BR112021014522A2 - Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3 - Google Patents

Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3

Info

Publication number
BR112021014522A2
BR112021014522A2 BR112021014522A BR112021014522A BR112021014522A2 BR 112021014522 A2 BR112021014522 A2 BR 112021014522A2 BR 112021014522 A BR112021014522 A BR 112021014522A BR 112021014522 A BR112021014522 A BR 112021014522A BR 112021014522 A2 BR112021014522 A2 BR 112021014522A2
Authority
BR
Brazil
Prior art keywords
bispecific antibody
lag
antibody molecule
present
heavy chain
Prior art date
Application number
BR112021014522A
Other languages
English (en)
Inventor
Bingliang Chen
Haiqing Ni
Junjian Liu
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of BR112021014522A2 publication Critical patent/BR112021014522A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3. a presente invenção refere-se a uma molécula de anticorpo projetada artificialmente que compreende: uma cadeia polipeptídica de fórmula (i): vh-ch1-fc-x-vhh; e uma cadeia polipeptídica de fórmula (ii): vl-cl; em que: a vh representa uma região variável de cadeia pesada; o ch representa uma região constante de cadeia pesada; o fc compreende ch2, ch3 e, opcionalmente, ch4; o ch1, o ch2, o ch3 e o ch4 representam os domínios 1, 2, 3 e 4, respectivamente, da região constante de cadeia pesada; o x pode estar ausente ou representar um ligante, como um ligante flexível, quando presente; o vhh representa um sítio de ligação ao antígeno de domínio único, como um anticorpo de domínio único; a vl representa uma região variável de cadeia leve; a cl representa uma região constante de cadeia leve; opcionalmente, uma região de dobradiça está presente entre o ch1 e o fc.
BR112021014522A 2019-01-25 2020-01-23 Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3 BR112021014522A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910073261 2019-01-25
PCT/CN2020/073964 WO2020151762A1 (zh) 2019-01-25 2020-01-23 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体

Publications (1)

Publication Number Publication Date
BR112021014522A2 true BR112021014522A2 (pt) 2021-11-30

Family

ID=71735420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021014522A BR112021014522A2 (pt) 2019-01-25 2020-01-23 Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3

Country Status (11)

Country Link
US (1) US20220112284A1 (pt)
EP (1) EP3916016A4 (pt)
JP (1) JP2022518519A (pt)
KR (1) KR20210120008A (pt)
CN (1) CN113383017B (pt)
AU (1) AU2020212228A1 (pt)
BR (1) BR112021014522A2 (pt)
CA (1) CA3126881A1 (pt)
SG (1) SG11202108062PA (pt)
TW (1) TWI756621B (pt)
WO (1) WO2020151762A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2022268168A1 (zh) * 2021-06-23 2022-12-29 迈威(上海)生物科技股份有限公司 靶向lag-3和pd-l1的新型双特异抗体及其应用
WO2023078450A1 (en) * 2021-11-05 2023-05-11 Vibrant Pharma Limited Multispecific antibodies and uses thereof
CN114478789B (zh) * 2021-12-20 2024-06-14 安徽安科生物工程（集团）股份有限公司 抗pd-l1与ox40双特异性抗体及其用途
CN117186223B (zh) * 2022-05-31 2024-08-09 明济生物制药（北京）有限公司 抗pd-l1抗体及编码其的核酸、制备方法和应用
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2535349A1 (en) * 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
IL285335B2 (en) 2011-04-08 2023-12-01 Us Health Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
WO2013003555A1 (en) * 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR102442436B1 (ko) * 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CN106188305A (zh) * 2015-06-01 2016-12-07 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
CA3008244A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
HUE055972T2 (hu) * 2016-05-09 2022-01-28 Igm Biosciences Inc Anti-PD-L1 antitestek
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
ES2858091T3 (es) * 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP6670935B2 (ja) * 2016-08-04 2020-03-25 イノベント バイオロジックス（スチョウ） カンパニー リミテッド 抗ｐｄ−１ナノ抗体およびその使用
WO2018220446A1 (en) * 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CN110914303B (zh) * 2017-07-13 2023-06-02 南京维立志博生物科技有限公司 结合lag-3的抗体及其用途

Also Published As

Publication number Publication date
EP3916016A4 (en) 2022-11-02
KR20210120008A (ko) 2021-10-06
US20220112284A1 (en) 2022-04-14
JP2022518519A (ja) 2022-03-15
EP3916016A1 (en) 2021-12-01
AU2020212228A1 (en) 2021-08-19
CN113383017A (zh) 2021-09-10
CN113383017B (zh) 2023-04-28
SG11202108062PA (en) 2021-08-30
WO2020151762A1 (zh) 2020-07-30
TW202043277A (zh) 2020-12-01
TWI756621B (zh) 2022-03-01
CA3126881A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
BR112021014522A2 (pt) Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
AR069797A1 (es) Anticuerpos especificos bivalentes
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
RS53058B (en) SP35 ANTIBODIES AND THEIR APPLICATIONS
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
BR112021005722A2 (pt) moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente
EA201171463A1 (ru) АНТИТЕЛА ПРОТИВ EpCAM
PE20190212A1 (es) Anticuerpos anti_ige
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CL2022002647A1 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
NZ602320A (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.